Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

kelly smith

- PMLiVE

UK vaccinations top nine million as concerns rise over South Africa variant

Surge testing is set to take place in eight areas linked to variant

- PMLiVE

Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition

Viela's portfolio of assets includes FDA-approved NMOSD therapy Uplizna

regeneron headquarters

EMA launches rolling review of Regeneron’s COVID-19 antibody cocktail

Study suggests REGN-COV2 can reduce viral load in non-hospitalised patients with COVID-19

Ashfield Healthcare Communications rebrands as Ashfield Health

Ashfield Health, part of UDG Healthcare plc, announces transformational changes including the unveiling of a new Global President, a rebrand, and the launch of two new global agencies.

Inizio

- PMLiVE

Transforming clinical trial data into a long-term asset

Considering the future of the trial master file in the light of COVID-19 and accelerated digital transformation

A MERGER THAT MATTERS

Pegasus, Ashfield Digital and Creative and Cambridge Biomarketing relaunch as Mind+Matter     ‘First-in-class’ global agency conceived to confront the toughest challenges in healthcare and wellness   New global agency offers 24/7 access...

Inizio

- PMLiVE

UK orders 40 million additional doses of Valneva’s COVID-19 vaccine

The UK's vaccine portfolio now includes a total of 407 million doses from a number of companies

- PMLiVE

Well-funded life sciences firms are making long-term progress – and their investors are too

This is an exciting time for British biotech and pharma, as the intense efforts to find a solution to COVID-19 offer a way out of the pandemic

- PMLiVE

CHMP recommends EU approval for Amarin’s cardiovascular risk reduction drug

The drug is recommended for use in adult patients who are already receiving statin treatment

- PMLiVE

Q&A: Louise Sharp

PME interviews Makara Health's owner and managing director

- PMLiVE

Novartis, Bayer announce separate agreements to bolster COVID-19 vaccine manufacturing

Novartis will help manufacture Pfizer/BioNTech's vaccine and Bayer will do the same for CureVac's vaccine

- PMLiVE

J&J’s one-dose COVID-19 vaccine proves 66% effective in phase 3 trial

Vaccine was 57% effective against South African strain

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links